FDA Approves Baxdrostat for Resistant Hypertension

• by Kathryn Wighton

• May 18, 2026

First MCT8 deficiency therapy approved

Clinical studies showed reductions in circulating thyroid hormone levels and changes in heart rate and systolic blood pressure.

• by Kathryn Wighton

• September 29, 2026

• 3 min

Sacubitril/Valsartan Versus Angiotensin-Converting Enzyme Inhibitor/Angiotensin Receptor Blocker Across the Ejection Fraction Spectrum: A Multistate Real-World Cohort

• by MICHEL CHEDID EL HELOU, KARIM HOYEK, HARSH PATOLIA, MICHAEL HILL, ZIAD ZALAQUETT, HUNTER BLOCK-BEACH, ASHISH SARRAJU, AMANDA R. VEST, NANCY M. ALBERT, RANDALL C. STARLING, TREJEEVE MARTYN

• October 10, 2026

Influence of left ventricular ejection fraction on the clinical outcome of percutaneous coronary interventions in heart transplant patients

• by Luisa Elbinger, Tobias Schupp, Michael Behnes, Ibrahim Akin, Angelika Costard-Jäckle, Rene Schramm, Tanja Rudolph, Volker Rudolph, Mohamed Ayoub

• October 7, 2026